You are here

P&T® Journal contents for June 2008

Features

Letter to the Editor
Marjorie Gatlin, MD
Cover Story
Advances in medical technologies have led to improved diagnoses and treatments, but medical devices do not always undergo the rigorous review process that is applied to drugs. To control costs, some health care facilities are becoming more selective in how they evaluate new devices.
C. Lee Ventola, MS
Technology
Because of the complex process involved in adding bar codes to all drug packages in order to prevent fraud, it might be difficult for pharmacies to fulfill the requirements of the e-Pedigree law, even by the target date of 2011.
Stephen Barlas
Medically accepted off-label uses of azacitidine (Vidaza) and a new indication for lubiprostone (Amitiza) are discussed.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Presentations cover iloperidone (Fanapta) for schizophrenia, asenapine for bipolar disorder, and virtual reality sessions for patients with post-traumatic stress disorder.
Walter Alexander
P&T Snapshot
According to a 2007 report, most dermatologists predicted that biologic therapies would be used more frequently in the next year; did not follow formularies they considered too restrictive; and expressed concern about denials of paper claims and reimbursements for surgical procedures combined with office visits.
Noah Scheinfeld, MD, John Jesitus, MA, and Peter Sonnenreich, MA

Departments

Editorial
David Nash, MD, MBA, offers strategies for current workers and young people preparing to enter an evolving pharmaceutical industry.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, reports on a survey in which many respondents said they had put off filling prescriptions, cut back on doses, or bought drugs illegally from other countries because of the high cost of prescribed drugs.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the damage that can be done when the FDA does not approve drug ads before they are broadcast on television.
Stephen Barlas
From Advair to Taclonex, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Drs. Maddox and Rahman review etonogestrel ­(Im­planon), a contraceptive.
Dionne D. Maddox, PharmD, and Zahra Rahman, PharmD